VolitionRx Limited (VNRX)
NYSEAMERICAN: VNRX · Real-Time Price · USD
0.6900
+0.0336 (5.12%)
Aug 29, 2025, 4:00 PM - Market closed
VolitionRx Revenue
VolitionRx had revenue of $406.69K in the quarter ending June 30, 2025, with 2.75% growth. This brings the company's revenue in the last twelve months to $1.32M, up 35.10% year-over-year. In the year 2024, VolitionRx had annual revenue of $1.23M with 59.10% growth.
Revenue (ttm)
$1.32M
Revenue Growth
+35.10%
P/S Ratio
49.78
Revenue / Employee
$15,521
Employees
85
Market Cap
74.24M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1.23M | 458.21K | 59.10% |
Dec 31, 2023 | 775.30K | 468.91K | 153.04% |
Dec 31, 2022 | 306.39K | 216.36K | 240.30% |
Dec 31, 2021 | 90.04K | 76.60K | 570.25% |
Dec 31, 2020 | 13.43K | -3.66K | -21.43% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
VNRX News
- 17 days ago - VolitionRx Limited (VNRX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 18 days ago - VolitionRx Limited Announces Second Quarter 2025 Financial Results and Business Update - PRNewsWire
- 24 days ago - VolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update - PRNewsWire
- 4 weeks ago - VolitionRx Announces Pricing of $1.2 Million Registered Direct Offering - PRNewsWire
- 6 weeks ago - Nu.Q® Discover Expands Global Adoption and Epigenetic Innovation - PRNewsWire
- 7 weeks ago - Volition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of Nucleosomes - PRNewsWire
- 2 months ago - Volition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure - PRNewsWire
- 3 months ago - Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties - PRNewsWire